Page 2 - Narcolepsy Type News Today : Breaking News, Live Updates & Top Stories | Vimarsana

20 Fastest Growing Biotech Companies in the US

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In The US. The biotechnology sector in the United States is witnessing a surge […]

United statesDemyelinating polyneuropathyEli lillyDtx pharmaJohna nortonAmicus therapeutics incAmgen incRegeneron pharmaceuticals incGilead sciences incBiopharma global incBiopharma solutionsBiomarin pharmaceutical incMerck co incAmbrx biopharma incBaxter international incAmerica most just companies

A Decade Of Innovation: How This CEO Transformed A Global Pharma Giant

In a decade, Christophe Weber remade Takeda into a global pharma leader, shifting from a fragmented structure to a unified innovator.

United statesUnited kingdomChristophe weberGiles platfordJulie kimPallavi gargTakeda qdengaTakeda pharmaceuticalPlasma derived therapiesEmerging marketsGlobal oncology productsNarcolepsy typePlaque psoriasisHealth careLife sciencesRare disease

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkJoe oconnorYuko yoneyamaChris stammBarbara shecterGabriel friedmanExchange commissionUpcoming scientific congressBell canadaInternational mediaTakeda pharmaceutical company limitedNational postBusiness wireRapidly initiateFirst global phase

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK861 an Oral Orexin Agonist in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.

United statesYuko yoneyamaTakeda pharmaceutical company limitedExchange commissionUpcoming scientific congressKey secondary endpoints were metNarcolepsy typeGenerally safeResults willUpcoming scientificWakefulness testAnnual reportMedia contactTakeda tak861 orexin receptor 2 ox2r narcolepsy type 1 nct05687903 nct05687916 nt1 nt2 maintenance of wakefulness test epworth sleepiness scale weekly cataplexy rate sarah sheikh gastrointestinal inflammation rare diseases plasmaderived therapies oncology neuroscience vaccines

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonis

− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial− TAK-861 Was Found to be Generally Safe and Well-Tolerated− Results Will be Presented at an Upcoming Scientific CongressOSAKA, Japan & CAMBRIDGE, Mass. (BUSINESS WIRE) Takeda (TSE:4502/NYSE:TAK) today announced positive topline resu.

United statesYuko yoneyamaUpcoming scientific congressTakeda pharmaceutical company limitedExchange commissionKey secondary endpoints were metNarcolepsy typeGenerally safeResults willUpcoming scientificWakefulness testAnnual report